Abbott Backs Down In Kaletra Pricing Fight

Law360, New York (April 11, 2007, 12:00 AM EDT) -- Abbott Laboratories said Tuesday it will slash the price of Kaletra by more than half in a slew of developing nations, following months of international pressure over the pharmaceutical giant's drug pricing policies in Thailand, which recently broke a patent on the HIV/AIDS treatment.

The drug maker said it will offer Kaletra, its “second-line” treatment for HIV/AIDS, to the governments of more than 40 low and low-middle income countries and nongovernmental organizations at $1,000 per patient per year.

That price tag is lower than any generic...
To view the full article, register now.